Enovis (NYSE:ENOV) PT Lowered to $62.00 at Evercore ISI

Enovis (NYSE:ENOV) had its price objective decreased by Evercore ISI from $70.00 to $62.00 in a research report sent to investors on Tuesday, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

Other research analysts also recently issued research reports about the company. Needham & Company LLC restated a buy rating and issued a $82.00 target price on shares of Enovis in a research note on Friday, May 3rd. JPMorgan Chase & Co. initiated coverage on Enovis in a research report on Thursday, June 13th. They set a neutral rating and a $53.00 price target for the company. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Enovis presently has an average rating of Moderate Buy and an average target price of $71.44.

Enovis Stock Up 0.8 %

Shares of NYSE ENOV opened at $44.69 on Tuesday. Enovis has a 52 week low of $43.04 and a 52 week high of $66.14. The business has a 50-day simple moving average of $49.16 and a two-hundred day simple moving average of $55.64. The company has a quick ratio of 1.03, a current ratio of 2.10 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.45 billion, a P/E ratio of -29.79 and a beta of 1.92.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, May 2nd. The company reported $0.50 EPS for the quarter, hitting the consensus estimate of $0.50. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. The business had revenue of $516.00 million during the quarter, compared to the consensus estimate of $505.62 million. During the same quarter last year, the company earned $0.44 EPS. The firm’s revenue was up 27.0% compared to the same quarter last year. Research analysts anticipate that Enovis will post 2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enovis

Large investors have recently modified their holdings of the company. Fidelis Capital Partners LLC purchased a new position in shares of Enovis during the 1st quarter valued at about $34,000. Principal Securities Inc. purchased a new position in Enovis in the 4th quarter worth approximately $41,000. Benjamin F. Edwards & Company Inc. increased its stake in Enovis by 97.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 846 shares of the company’s stock worth $47,000 after purchasing an additional 417 shares during the period. GAMMA Investing LLC purchased a new position in Enovis in the 4th quarter worth approximately $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in Enovis in the 1st quarter worth approximately $122,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.